KOSDAQ - Delayed Quote KRW

Amicogen, Inc. (092040.KQ)

Compare
4,360.00 +25.00 (+0.58%)
At close: 3:30 PM GMT+9
Loading Chart for 092040.KQ
DELL
  • Previous Close 4,335.00
  • Open 4,310.00
  • Bid 4,340.00 x --
  • Ask 4,360.00 x --
  • Day's Range 4,225.00 - 4,390.00
  • 52 Week Range 3,970.00 - 9,400.00
  • Volume 277,896
  • Avg. Volume 352,633
  • Market Cap (intraday) 258.369B
  • Beta (5Y Monthly) 1.01
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Nov 5, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 29, 2015
  • 1y Target Est --

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company offers bio-ingredients, such as N-acetylglucosamine for skin moisturizing and joint health; pinitol/D-chiro-inositol; collagen peptide and collagen tripeptide for skin and health; chitoslim and chitosan oligosaccharides, as well as fucoxanthin, curezyme, food enzyme, and bamboo salt. It also offers specialty enzymes, including CX, SP, etc. for pharmaceutical, food, and feed sectors. In addition, the company offers K-nutra, a healthcare brand; and KeyClean, a disinfectant brand. Further, it provides protein purification resins. Amicogen, Inc. was founded in 2000 and is headquartered in Jinju-si, South Korea.

www.amicogen.com

225

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 092040.KQ

View More

Performance Overview: 092040.KQ

Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

092040.KQ
42.33%
KOSPI Composite Index
2.31%

1-Year Return

092040.KQ
32.46%
KOSPI Composite Index
5.33%

3-Year Return

092040.KQ
74.80%
KOSPI Composite Index
13.73%

5-Year Return

092040.KQ
60.98%
KOSPI Composite Index
25.87%

Compare To: 092040.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 092040.KQ

View More

Valuation Measures

Annual
As of 10/16/2024
  • Market Cap

    219.81B

  • Enterprise Value

    369.45B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.63

  • Price/Book (mrq)

    1.31

  • Enterprise Value/Revenue

    2.32

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -23.21%

  • Return on Assets (ttm)

    -0.64%

  • Return on Equity (ttm)

    -18.16%

  • Revenue (ttm)

    158.98B

  • Net Income Avi to Common (ttm)

    -36.91B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    25.69B

  • Total Debt/Equity (mrq)

    84.56%

  • Levered Free Cash Flow (ttm)

    -109.87B

Research Analysis: 092040.KQ

View More

Company Insights: 092040.KQ

Research Reports: 092040.KQ

View More

People Also Watch